EMV Capital backed SageTech Medical gets a boost from Guy’s and St.Thomas’ NHS Trust study

Cutting edge solution to capture waste anaesthetic gasses, avoiding greenhouse gases

EMV Capital (“EMVC”), the VC investor specialising in early-stage high-growth deep tech companies, is delighted to provide this update on positive results from a recent study by Guy’s and St Thomas’ NHS Foundation Trust (“the Trust”) regarding its portfolio company, SageTech Medical (“SageTech”).  EMV Capital is a wholly owned subsidiary of NetScientific plc (AIM:NSCI), a life sciences and technology commercialisation and investment group.

SageTech is a medical device company focused on the capture and recycling of environmentally polluting anaesthetic gasses from the human and veterinary healthcare sectors. The positive results from the Trust’s study, concerning its gas capturing system, has been published by the Association of Anaesthetists. Anaesthetic gases globally are responsible for an estimated 3.1M tonnes of CO2e emissions every year.

The study concluded that SageTech’s SID-Dock capture system has high baseline efficiency of 94.8%, when used in the clinical setting without the variability of a patient being present. The study also concluded that the Trust can now assess this technology within a full clinical patient setting.

SageTech’s unique solution safely and efficiently captures waste volatile anaesthetic onto a carbon filter contained inside a reusable capture canister (SID-Can). Two SID-Cans are housed inside a SID-Dock capture machine which connects seamlessly to existing hospital equipment.

Full SID-Cans are collected from hospitals and emptied at regional recovery hubs before being returned for reuse.  Recovered liquid waste is then transported in bulk to a purification and manufacturing facility in Devon, where it is recycled for future reuse by hospitals.

The full study has been published online and is available via this link.

Dr Iain Menneer, CEO of SageTech Medical, commented:

“Inhalational anaesthetic agents are potent greenhouse gasses.  The NHS’ long term plan sets a target of a 40% reduction in greenhouse gas emissions, and while some progress has been made in that regard, new opportunities such as our inhalation agent waste capture technology are important for further reductions.

“We are therefore delighted with the independent study by Guy’s and St Thomas’ NHS Foundation Trust which confirmed the high baseline efficiency of our solution when used in the clinical setting without the variability of a patient being present.  We look forward to a follow up study, assessing our technology within a full clinical patient setting.

“Looking at the issue that we address more widely, we believe that DEFRA in the UK should step in and regulate pollution by hospitals, which would continue the long tradition of the UK leading by example on medical and sustainability issues.”

Dr Ilian Iliev, Managing Director of EMV Capital, added: 

“We are very pleased with the SageTech team’s progress in this important area. Collecting and recycling waste volatile anaesthetic agents from hospitals and veterinary clinics reduces the significant burden associated with their virgin manufacture, and the environmental impact of their release. 

“SageTech’s circular economy solution helps to protect the health of people and our planet, while saving costs. We are therefore delighted with Guy’s and St Thomas’ very positive findings in their conclusion of their independent study of SageTech’s pioneering solution.”

About EMV Capital

EMV Capital is an award-winning VC investor specialising in early stage high-growth deep tech companies in the life science, sustainability, and industrials sectors in the UK and internationally.

EMV Capital develops unique investment strategies for each portfolio company, drawing on its EIS investment fund and extensive network of private investors, family offices, institutions, and corporate VCs. Delivery and successful execution of these investment strategies enables innovative portfolio companies to raise funding to drive transformational growth.

EMV Capital is a wholly owned subsidiary of NetScientific plc (AIM:NSCI), a life sciences and technology commercialisation and investment group.

EMV Capital has a multi-disciplinary team of specialist investors, portfolio managers, capital raisers, legal, finance, marketing, and support staff.  The company is focused on primary and secondary investments, through debt and/or equity.


For any enquiries, please contact Belvedere Communications:

John West:           +44 (0)203 008 6866


Llew Angus          +44 (0)203 008 6867


About SageTech Medical

Recognising and responding to the global climate crisis, SageTech Medical was founded in Devon in 2015 by a team of scientists and engineers with a goal to reduce waste anaesthetic agents that are harmful to the environment.

SageTech Medical are a medical device and pharmaceutical company that are focused on the research, design, manufacture, and distribution of cutting-edge, proprietary technologies that enable them to offer a safe, sustainable, and easy to use circular economy solution for the capture, recovery, and recycling of environmentally harmful waste volatile anaesthetic gases.

It is vital to protect the environment for future generations, and by preventing these exhaled gases from polluting the atmosphere, SageTech Medical are providing hospitals with a straightforward, unique solution to enable them to make a real difference to the environment.


Leave a comment

The reCAPTCHA verification period has expired. Please reload the page.


Don’t invest unless you’re prepared to lose all the money you invest. This is a high risk investment and you are unlikely to be protected if something goes wrong. Take 2 mins to learn more.